valproic acid has been researched along with Deafness, Transitory in 6 studies
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Valproic acid (VPA) is an important and commonly used histone deacetylase (HDAC) inhibitor for class I (HDAC1, 2, 3, and 8) and class IIa (HDAC4, 5, 7, and 9)." | 5.91 | Valproic Acid Inhibits Progressive Hereditary Hearing Loss in a KCNQ4 Variant Model through HDAC1 Suppression. ( Cho, HH; Choi, YM; Lee, S; Nam, YS, 2023) |
| "Valproic acid (VPA) has been reported to cause cognitive decline and parkinsonism that are reversed with cessation of medication." | 5.37 | Reversible dementia and gait disturbance after prolonged use of valproic acid. ( Evans, MD; Shinar, R; Yaari, R, 2011) |
| " Hearing loss was associated with valproic acid and low-dose acetylsalicylic acid exposure during pregnancy." | 3.88 | In utero drug exposure and hearing impairment in 2-year-old children A case-control study using the EFEMERIS database. ( Araujo, M; Benevent, J; Damase-Michel, C; Durrieu, G; Foch, C; Lacroix, I; Montastruc, JL; Weckel, A, 2018) |
| " DBA/2J mice, which are a model for progressive hearing loss, were injected subcutaneously with one or a combination of the following reagents: | 3.81 | Attenuation of progressive hearing loss in DBA/2J mice by reagents that affect epigenetic modifications is associated with up-regulation of the zinc importer Zip4. ( Fujii, M; Matsunaga, T; Miya, F; Mutai, H; Tsunoda, T, 2015) |
| "Valproic acid (VPA) is an important and commonly used histone deacetylase (HDAC) inhibitor for class I (HDAC1, 2, 3, and 8) and class IIa (HDAC4, 5, 7, and 9)." | 1.91 | Valproic Acid Inhibits Progressive Hereditary Hearing Loss in a KCNQ4 Variant Model through HDAC1 Suppression. ( Cho, HH; Choi, YM; Lee, S; Nam, YS, 2023) |
| "Valproic acid (VPA) has been reported to cause cognitive decline and parkinsonism that are reversed with cessation of medication." | 1.37 | Reversible dementia and gait disturbance after prolonged use of valproic acid. ( Evans, MD; Shinar, R; Yaari, R, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 2 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Wakizono, T | 1 |
| Nakashima, H | 1 |
| Yasui, T | 1 |
| Noda, T | 1 |
| Aoyagi, K | 1 |
| Okada, K | 1 |
| Yamada, Y | 1 |
| Nakagawa, T | 1 |
| Nakashima, K | 1 |
| Nam, YS | 1 |
| Choi, YM | 1 |
| Lee, S | 1 |
| Cho, HH | 1 |
| Foch, C | 1 |
| Araujo, M | 1 |
| Weckel, A | 1 |
| Damase-Michel, C | 1 |
| Montastruc, JL | 1 |
| Benevent, J | 1 |
| Durrieu, G | 1 |
| Lacroix, I | 1 |
| Mutai, H | 1 |
| Miya, F | 1 |
| Fujii, M | 1 |
| Tsunoda, T | 1 |
| Matsunaga, T | 1 |
| Evans, MD | 1 |
| Shinar, R | 1 |
| Yaari, R | 1 |
| Hori, A | 1 |
| Kataoka, S | 1 |
| Sakai, K | 1 |
| Hirose, G | 1 |
| Iwasaki, N | 1 |
| Horiguchi, A | 1 |
| Takashima, M | 1 |
| Tomoda, K | 1 |
6 other studies available for valproic acid and Deafness, Transitory
| Article | Year |
|---|---|
Growth factors with valproic acid restore injury-impaired hearing by promoting neuronal regeneration.
Topics: Animals; Hearing Loss; Humans; Mice; Neurons; Regeneration; Valproic Acid | 2021 |
Valproic Acid Inhibits Progressive Hereditary Hearing Loss in a KCNQ4 Variant Model through HDAC1 Suppression.
Topics: Animals; Deafness; Hair Cells, Auditory; Hearing Loss; Hearing Loss, Sensorineural; Histone Deacetyl | 2023 |
In utero drug exposure and hearing impairment in 2-year-old children A case-control study using the EFEMERIS database.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticonvulsants; Aspirin; Case-Control Studies; Child, Pres | 2018 |
Attenuation of progressive hearing loss in DBA/2J mice by reagents that affect epigenetic modifications is associated with up-regulation of the zinc importer Zip4.
Topics: Animals; Catechin; Cation Transport Proteins; Cochlea; Down-Regulation; Epigenesis, Genetic; Evoked | 2015 |
Reversible dementia and gait disturbance after prolonged use of valproic acid.
Topics: Aged; Anticonvulsants; Cerebral Ventricles; Dementia; Female; Gait Disorders, Neurologic; Hearing Lo | 2011 |
Valproic acid-induced hearing loss and tinnitus.
Topics: Adult; Anticonvulsants; Audiometry; Child; Female; Hearing Loss; Humans; Tinnitus; Valproic Acid | 2003 |